{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:04:16Z","timestamp":1788368656121,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T00:00:00Z","timestamp":1450915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejca.2015.12.014","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T20:56:01Z","timestamp":1454360161000},"page":"122-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy"],"prefix":"10.1016","volume":"56","author":[{"given":"Nobuhito","family":"Araki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Yonemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hiruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kunisada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Matsumine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2015.12.014_bib1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminoncol.2009.06.004","article-title":"Translocation-related sarcomas","volume":"36","author":"Mertens","year":"2009","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.014_bib2","first-page":"1941","article-title":"Soft tissue sarcomas of adults: state of the translational science","volume":"9","author":"Borden","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2015.12.014_bib3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","article-title":"Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas","volume":"11","author":"Edmonson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2015.12.014_bib4","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.1995.13.7.1537","article-title":"Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group","volume":"13","author":"Santoro","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.12.014_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/1471-2407-13-385","article-title":"Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review","volume":"13","author":"Sharma","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2015.12.014_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","article-title":"Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action","volume":"37","author":"Erba","year":"2001","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.ejca.2015.12.014_bib7","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2015.12.014_bib8","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D'Incalci","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.014_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1593\/neo.101202","article-title":"Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells","volume":"13","author":"Grohar","year":"2011","journal-title":"Neoplasia"},{"issue":"44","key":"10.1016\/j.ejca.2015.12.014_bib10","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/onc.2013.462","article-title":"Mode of action of trabectedin in myxoid liposarcomas","volume":"33","author":"Di Giandomenico","year":"2014","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.014_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(15)70098-7","article-title":"Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomized, open-label, phase 2 study","volume":"16","author":"Kawai","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.014_bib12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10637-014-0094-5","article-title":"Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma","volume":"32","author":"Ueda","year":"2014","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.ejca.2015.12.014_bib13","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs\u2013twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2015.12.014_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mds470","article-title":"Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy","volume":"24","author":"Penel","year":"2013","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2015.12.014_bib15","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1016\/j.ejca.2012.05.012","article-title":"A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas","volume":"48","author":"Le Cesne","year":"2012","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2015.12.014_bib16","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","article-title":"Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg","volume":"41","author":"Zalcberg","year":"2005","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2015.12.014_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2015.12.014_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(15)70031-8","article-title":"Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial","volume":"16","author":"Le Cesne","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2015.12.014_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/14740338.2013.829037","article-title":"Safety evaluation of trabectedin in treatment of soft-tissue sarcomas","volume":"12","author":"Martin-Liberal","year":"2013","journal-title":"Expert Opin Drug Saf"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T20:10:08Z","timestamp":1668715808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915011582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":19,"alternative-id":["S0959804915011582"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}